Page 3 - Thursday Malaysia News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Малайзия с 12 мая почти на месяц уходит в режим изоляции из-за COVID-19
interfax.by - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from interfax.by Daily Mail and Mail on Sunday newspapers.
中美元首通话释放积极信号！道指盘中创新高，比特币刷新纪录高位_国元首
sohu.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sohu.com Daily Mail and Mail on Sunday newspapers.
中美元首通话释放积极信号！道指盘中创新高，比特币刷新纪录高位 _ 证券时报网
stcn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from stcn.com Daily Mail and Mail on Sunday newspapers.
路透新闻部
2 分钟阅读
KUALA LUMPUR, Feb 4 (Reuters) - Malaysia’s Solution Group Bhd said on Thursday it has signed a term sheet agreement with the government to supply 3.5 million doses of COVID-19 vaccine jointly developed by China’s CanSino Biologics Inc and Beijing Institute of Biotechnology under the Academy of Military Medical Sciences.
The company, whose website shows it is an engineering as well as biopharmaceuticals business, said in a bourse filing that its wholly-owned unit Solution Biologics had signed the agreement on Jan. 29 with the Health Ministry.
The agreement will enable the subsidiary to enter into a definitive supply agreement to supply 3.5 million doses of the Recombinant Ad5-nCoV vaccine for the prevention of COVID-19, it said.
By Reuters Staff
2 Min Read
FILE PHOTO: Woman holds vials labelled COVID-19 Coronavirus Vaccine over dry ice in this illustration taken, December 5, 2020. REUTERS/Dado Ruvic/Illustration/File Photo/File Photo
KUALA LUMPUR (Reuters) - Malaysia’s Solution Group Bhd said on Thursday it has signed a term sheet agreement with the government to supply 3.5 million doses of COVID-19 vaccine jointly developed by China’s CanSino Biologics Inc and Beijing Institute of Biotechnology under the Academy of Military Medical Sciences.
The company, whose website shows it is an engineering as well as biopharmaceuticals business, said in a bourse filing that its wholly-owned unit Solution Biologics had signed the agreement on Jan. 29 with the Health Ministry.